Related Experiment Video
Updated: Jan 21, 2026

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
Published on: June 30, 2023
Effects of newly introduced antidiabetic drugs on autophagy
Milad Ashrafizadeh1, Habib Yaribeygi2, Stephen L Atkin3
1Department of Basic Science, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran.
Abstract:
Diabetes mellitus is a chronic metabolic disorder that has a complex molecular and cellular pathophysiology, resulting in its dynamic progression and that may show differing responses to therapy. The incidence of diabetes mellitus increases with age and requires additive therapeutic agents for its management. SGLT2i and DPP-4 inhibitors and GLP-1 receptor agonists (GLP-1RA) are newly introduced antidiabetic drugs that work through differing mechanisms; DPP-4 inhibitors maintain the endogenous level of GLP1; GLP-1RA result in pharmacological levels of GLP1, whilst SGLT2i act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes and in contrast to other antidiabetic drugs, do not inherently cause hypoglycemia in therapeutic doses. Autophagy as a highly conserved mechanism to maintain cell survival and homeostasis by degradation of damaged or aged organelles and components, and recognised to be increasingly important in diabetes. In the present review, we discuss the modulatory effects of these newly introduced antidiabetic drugs on the autophagy process.
Insights
New antidiabetic drugs, including SGLT2 inhibitors and GLP-1 receptor agonists, modulate autophagy. This review explores how these therapies impact cellular processes crucial for managing diabetes mellitus.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Cellular Biology
Background:
- Diabetes mellitus is a chronic metabolic disorder with complex pathophysiology, increasing with age.
- Newer antidiabetic agents like SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) offer novel therapeutic mechanisms.
- Autophagy, a cellular degradation process, plays a critical role in maintaining homeostasis and is increasingly recognized in diabetes.
Purpose of the Study:
- To review the modulatory effects of SGLT2i, DPP-4 inhibitors, and GLP-1RA on the autophagy process in diabetes.
- To elucidate the impact of these novel antidiabetic drugs on cellular mechanisms relevant to diabetes management.
Main Methods:
- Literature review of studies investigating the effects of SGLT2i, DPP-4 inhibitors, and GLP-1RA on autophagy.
- Analysis of the distinct mechanisms of action for each drug class.
Main Results:
- SGLT2i, DPP-4 inhibitors, and GLP-1RA demonstrate efficacy in diabetes management without inherent hypoglycemia risk.
- These drugs exhibit modulatory effects on autophagy, influencing cellular survival and homeostasis.
- The specific impact on autophagy varies depending on the drug class and its mechanism.
Conclusions:
- Novel antidiabetic drugs, including SGLT2i and GLP-1RA, interact with the autophagy pathway.
- Understanding these drug-autophagy interactions may offer new insights into diabetes treatment and cellular health.
- Further research is warranted to fully explore the therapeutic potential of targeting autophagy in diabetes management.
Related Concept Videos
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Introducing Social Perception
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...

